Focused On-demand Library for Zinc finger protein 462

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96JM2

UPID:

ZN462_HUMAN

Alternative names:

Zinc finger PBX1-interacting protein

Alternative UPACC:

Q96JM2; Q5T0T4; Q8N408

Background:

Zinc finger protein 462, alternatively known as Zinc finger PBX1-interacting protein, plays a pivotal role in transcription regulation by modulating chromatin structure. It is instrumental in embryonic stem cells' pluripotency and differentiation, influencing key factors such as SOX2, POU5F1/OCT4, and NANOG. Additionally, it contributes to neuronal development and neural cell differentiation, showcasing its significance in the intricate processes of cellular development.

Therapeutic significance:

Linked to Weiss-Kruszka syndrome, a condition characterized by developmental delays, craniofacial abnormalities, and variable congenital heart defects, Zinc finger protein 462's genetic variants underscore its clinical relevance. Understanding the role of Zinc finger protein 462 could open doors to potential therapeutic strategies for managing and potentially treating Weiss-Kruszka syndrome.